Metahexamide
Metahexamide.svg
Names
Preferred IUPAC name
3-Amino-N-(cyclohexylcarbamoyl)-4-methylbenzene-1-sulfonamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.008.434 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C14H21N3O3S/c1-10-7-8-12(9-13(10)15)21(19,20)17-14(18)16-11-5-3-2-4-6-11/h7-9,11H,2-6,15H2,1H3,(H2,16,17,18) ☒N
    Key: XXYTXQGCRQLRHA-UHFFFAOYSA-N ☒N
  • InChI=1/C14H21N3O3S/c1-10-7-8-12(9-13(10)15)21(19,20)17-14(18)16-11-5-3-2-4-6-11/h7-9,11H,2-6,15H2,1H3,(H2,16,17,18)
    Key: XXYTXQGCRQLRHA-UHFFFAOYAB
  • CC1=C(C=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2)N
Properties
C14H21N3O3S
Molar mass 311.4 g/mol
Pharmacology
A10BB10 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]

References

  1. ^ Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.